key: cord-0935142-eyrtld9k
authors: Shinzato, Yutaro; Sakihara, Eiryu; Kishihara, Yuki; Kashiura, Masahiro; Yasuda, Hideto; Moriya, Takashi
title: Clinical application of skin antisepsis using aqueous olanexidine: a scoping review
date: 2022-01-07
journal: Acute Med Surg
DOI: 10.1002/ams2.723
sha: 1ed2d86bfad47c1fc585b43706a833a29ffd59c1
doc_id: 935142
cord_uid: eyrtld9k

Surgical site infections (SSIs) and catheter‐related bloodstream infections (CRBSIs) caused by bacteria from surfaces poorly disinfected with chlorhexidine gluconate (CHG) and povidone‐iodine (PVP‐I) are increasing. Olanexidine gluconate (OLG) was developed in 2015 in Japan to prevent SSI and CRBSI caused by bacteria resistant to CHG and PVP‐I. This scoping review aimed to identify the knowledge gap between what is known and what is not known about the disinfection efficacy of OLG. We searched MEDLINE through PubMed, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the International Clinical Trials Registry Platform search database, ClinicalTrials.gov, and the Web‐based database of Japanese medical articles for works published to July 18, 2021. Manual reference searches were also carried out. A total of 131 studies were screened. Forty‐seven studies were included in this review and classified into two major categories: studies on pharmacological effects and spectrum (n = 29) and studies on clinical and adverse effects (n = 18). Olanexidine gluconate showed bactericidal activity against methicillin‐resistant Staphylococcus aureus and vancomycin‐resistant enterococci, in addition to common Gram‐positive and Gram‐negative bacteria. In clinical settings, although there is limited evidence on SSI prevention, 1.5% OLG might be more effective than 10% PVP‐I and 1% CHG in preventing SSI. However, the clinical usefulness of OLG is unclear due to the limited number of clinical studies. Also, clinical research is limited to studies targeting SSI prevention, and there are no clinical studies on CRBSI. Further clinical studies are needed on SSI and CRBSI prevention.

M ICROORGANISMS ON THE skin surface can cause various infections in hospital settings. Among such infections, surgical site infection (SSI) and catheter-related bloodstream infection (CRBSI) lead to higher mortality rates, longer hospital stays, and higher medical costs. [1] [2] [3] [4] Various disinfectants have been developed to prevent SSIs and CRBSIs. Regarding the balance between disinfection efficacy and adverse events, the guidelines of the Centers for Disease Control and Prevention and the National Institute for Health and Clinical Excellence recommend the use of alcohol-containing chlorhexidine gluconate (CHG). 5, 6 Chlorhexidine gluconate use is associated with a lower incidence of CRBSI, when compared to the use of povidoneiodine (PVP-I) or alcohol. 7 Thus, CHG is recommended for CRBSI prevention. [8] [9] [10] [11] However, the occurrence of SSI and CRBSI caused by bacteria on surfaces that are poorly sterilized with CHG or PVP-I has been increasing in recent years. 5,10-13 Specifically, Staphylococcus aureus and Enterococcus species are the most common causative bacteria of SSIs and CRBSIs. 14, 15 Clinical studies have shown that PVP-I is ineffective in disinfecting surfaces with enterococci, which include vancomycin-resistant enterococci (VRE). 16, 17 Furthermore, the studies have reported the inefficacy of CHG in disinfecting surfaces with methicillin-resistant S. aureus (MRSA) and VRE. 18, 19 To prevent SSIs and CRBSIs caused by bacteria resistant to CHG and PVP-I, olanexidine [1-(3,4-dichlorobenzyl)-5-octylbiguanide] gluconate (OLG) was developed in Japan in 2015. In vitro, OLG has a broad-spectrum, disinfecting, and fast-acting activity against drug-resistant bacteria. [20] [21] [22] [23] [24] [25] A randomized controlled trial (RCT) comparing the activity of OLG and PVP-I showed that OLG is superior to PVI in the prevention of SSIs. 26 Although some of the disinfection effects of OLG have been clarified, some aspects of the clinical use of OLG need clarification: whether OLG is more effective than CHG for skin disinfection, which is recommended for CRBSI and SSI prevention; whether CHG is effective in preventing non-SSI infections; and whether OLG is more effective than other disinfectants against resistant bacteria in clinical settings.

Therefore, we undertook a scoping review to clarify what is currently known and what remains unclear about OLG's disinfectant activity. Specifically, we focused on two points: OLG's pharmacological effect, including its spectrum and associated adverse events; and its clinical effects, including prevention of SSI and CRBSI. The results were summarized separately for each of these points.

on OLG, regardless of their design. The studies included in vitro studies of animals and humans, case reports, observational studies, and RCTs. Conference abstracts with unavailable full texts were excluded, due to insufficient information for this review. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist. 27 We searched MEDLINE through PubMed, the Cochrane Central Register of Controlled Trials (CEN-TRAL), the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the International Clinical Trials Registry Platform (ICTRP) search database, ClinicalTrials.gov, and the Web-based database of Japanese medical articles (Ichu-shi) for articles published to July 18, 2021. Manual reference searches were also undertaken as appropriate. When searching MEDLINE/CENTRAL/CINAHL, we used the following search terms: "olanexidine", "OPB-2045" (OPB; the development code of olanexidine), "olanedine", and "olanexidine gluconate". When searching Ichu-shi, the search terms used in the MEDLINE/CENTRAL/CINAHL search were translated into Japanese. There was no language restriction. The extracted studies were screened independently by two reviewers (ES and YS) to determine their eligibility for inclusion. Disagreements were discussed and resolved between the two reviewers. If the disagreement could not be resolved, the decision was left to a third reviewer (HY).

A TOTAL OF 131 studies (25 from PubMed, 13 from CENTRAL, 80 from Ichu-shi, six from CINAHL, two from the manual reference search, and five from ICTRP/ ClinicalTrials.gov) were screened (Fig. 1, Table S1 ). Twenty-nine studies were excluded during the first screening (duplicates, 11; unavailable full text, 18) . In the second screening that entailed a review of full texts, 50 studies were excluded: four in which OLG was not mentioned and 46 conference abstracts (Table S2) . Finally, 47 studies were included in the review.

Forty-seven studies were classified into two major categories based on their focus areas: studies on pharmacological effects and spectrum (n = 29) and studies on clinical and adverse effects (n = 18). The studies on pharmacological effects and spectrum were animal or in vitro studies. The studies on clinical and adverse effects were human studies ( Table 1) .

In many studies, CHG and PVP-I used were formulated without alcohol. In studies in which CHG and PVP-I with alcohol were used, supplementary explanations were provided.

Olanexidine gluconate is a biguanide antiseptic solution that was developed by Otsuka Pharmaceutical Factory, Inc. in 2015. To reduce skin irritation without decreasing its antimicrobial effect, the medicinal ingredient olanexidine (1-(3,4dichlorobenzyl)-5-octylbiguanide [OPB-2045] ) is converted to gluconate, and the solubilizer polyoxyethylene (20) polyoxypropylene (20) glycol (POEPOPG) is added to complete OPB. 23 The chemical formula is 1-(3,4-dichlorobenzyl)-5octylbiguanide mono-D-gluconate 28 (Fig. 2 ).

There were four studies on bactericidal action 23,28-30 and one on the inhibitory action of inflammatory chemokines. 31 

The mechanism underlying the bactericidal action of OLG differs between low and high concentrations, although the detailed mechanism has not been elucidated. At low concentrations (median effective dose [ED50], 8.4-25 lg/mL as the lower limit; no upper limit concentration), OLG has a higher affinity for bacterial surface proteins such as the lipoteichoic acid of Gram-positive bacteria and Ó 2022 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine lipopolysaccharide (LPS) of Gram-negative bacteria, compared to CHG with an ED50 of 27-610 lg/mL. 23 Similarly, for phospholipids such as lysyl-phosphatidylglycerol (L-PG) and phosphatidylethanolamine (PE), at a concentration higher than the minimal inhibitory concentration (0.63 lg/ mL against Gram-positive bacteria and 4.0 lg/mL against Gram-negative bacteria), OLG had a stronger disruptive effect than CHG on membranes containing L-PG and PE. 23 These actions cause irreversible leakage of intracellular components, which leads to a bactericidal effect. 23 23, 28 (with olanexidine at a concentration of 15 000 lg/mL), which means that it has both low and high concentration effects.

In addition to the bactericidal effects of OLG, it is reported that OLG has an inhibitory action on inflammatory chemokines. Nii et al. administered the LPS of Porphyromonas gingivalis to immortalized human oral keratinocytes, which are regarded as oral epithelial cells, and tested whether the inflammatory cytokines produced by human oral keratinocytes decreased after 0.1% OLG application. The levels of inflammatory cytokines such as interleukin-8, chemokine (C-C motif) ligand 20, and growth-regulated oncogene protein-a, which cause chronic inflammatory reactions such as periodontitis, decreased after 0.1% OLG application. This suggests that OLG could inhibit the inflammatory response. 31

Nine studies validated the spectrum: seven for bacteria and fungi [20] [21] [22] [23] [24] [25] 28 and four for viruses. 28 (Table 2) . For MRSA, two studies showed that 1.5% OLG was more effective for disinfection than 0.5% CHG and 10% PVP-I (Table 3) . 22, 25 In addition, two studies 20,24 compared whether the MBC of OLG, CHG, and PVP-I changed in the presence or absence of qacA/B, which encodes a disinfectant efflux pump thought to be responsible for methicillin resistance. The researchers reported that only the MBC of OLG remained unchanged in the presence or absence of qacA/B (Table 3) . However, 1.5% OLG was more effective in disinfection against VRE than 0.5% CHG and 10% PVP-I. 22 , 25 Inoue et al. 25 also compared the MBC of OLG, CHG, and PVP-I against MRSA and VRE: the MBC of OLG against MRSA and VRE was equal to or lower than that of CHG or PVP-I (Table 3) .

Regarding the bactericidal effect on resistant bacteria other than MRSA and VRE, such as methicillin-resistant Staphylococcus epidermidis, extended-spectrum b-lactamaseproducing Klebsiella pneumoniae, and multidrug-resistant P. aeruginosa, 1.5% OLG killed these bacteria within 15 s after 1.5% OLG application 21 (Table 3) . However, B. cepacia was not eliminated more than 30 min after 1.5% OLG application, 21, 23 and the bactericidal effect of 1.5% OLG on B. cepacia was comparable to those of CHG and PVP-I (concentrations unknown) reported in a previous study. 12 Furthermore, 1.5% OLG had a poor bactericidal effect on Mycobacterium, consistent with the previously reported bactericidal effect of CHG (concentration unknown). 21, 35 Fungi Surfaces contaminated with Candida albicans and Malassezia furfur were disinfected within 30 s after 1.5% OLG application, whereas those contaminated with Microsporum canis and Trichophyton rubrum were disinfected within 3 and 10 min, respectively, after 1.5% OLG application. 21 However, Aspergillus brasiliensis was not eliminated even after 10 min of 1.5% OLG application 21 (Table 2) .

Viruses Influenza A virus, which has an envelope, was inactivated by 1.5% OPB for more than 1 min after application. However, feline calicivirus, which does not have an envelope, was not inactivated even 10 min after application. 28 In addition, Imai et al. 33 

Four studies were identified: three on the time-to-onset of bactericidal action [20] [21] [22] and two on the duration of bactericidal action. 22 

As mentioned in the section on spectrum, 1.5% OLG showed a disinfectant effect on a wide range of bacteria within 30 s (Tables 2 and 3) . Furthermore, Nishioka et al. 22 compared the bacterial counts of MRSA, S. epidermidis, VRE, Acinetobacter baumannii, Corynebacterium minutissimum, and Cutibacterium acnes, which were problematic in SSI, while comparing 1.5% OLG with 0.5% CHG and 10% PVP-I. Compared to 10% PVP-I and 0.5% CHG, 1.5% OPB showed an equivalent or greater reduction in bacterial counts 30 s after application.

Nishioka et al. 22 discussed the amount of disinfectant left in the stratum corneum after 4, 8, and 12 h of rinsing immediately after application. The concentration of 1.5% OLG left was 2.8-4.2 times higher in the stratum corneum than that of 1.5% CHG at all incubation times. This indicated that the rate of washout for 1.5% OLG was lower than that for 1.5% CHG. The proportion of bacteria after 12 h of 1.5% OLG application was lower than that after 4 and 8 h, indicating that the bactericidal action time was approximately 12 h. Regarding the long action time of OLG, the reduced effectiveness of disinfectants was generally attributed to sweating and contamination with blood. 37 Nakata et al. 36 evaluated the effectiveness of reducing bacteria after 10 min and 6 h of application of 0.5% CHG, 10% PVP-I, and 1.5% OLG on blood-contaminated monkey skin. The decrease in bacterial count after 1.5% OLG application was higher than that after the application of 0.5% CHG or 10% PVP-I, indicating that the decrease in bactericidal action with blood contamination was smallest after 1.5% OLG application, compared to 0.5% CHG and 10% PVP-I. 36 Pharmacokinetics (animal studies)

Thirteen studies on pharmacokinetics were identified: three on dermal absorption, 22,38,39 eight on metabolism and excretion, 38, [40] [41] [42] [43] [44] [45] [46] and five on biogenesis. 42, [47] [48] [49] [50] Concerning dermal absorption, Kudo et al. reported two studies: one in which the radioactivity at the injection site was measured at 1, 8, and 24 h after dermal administration of biguanide 14 C-labeled OLG (concentration unknown) in rats 38 and another in which the dermal absorption of 0.1% OLG after the application was measured in intact and damaged rat skin. 39 Olanexidine gluconate remained in the skin and was poorly absorbed in both studies. Regarding reproduction and development, Fujio et al. and Takenaka et al. 42, [47] [48] [49] [50] carried out animal experiments on rats and rabbits. Parental animals treated subcutaneously with 0.04%-0.0004% OLG showed no effect of the drug application on the estrus cycle of female rats, fertilization rate, nursery condition of mothers after birth, and all cycles up to fetal development.

Considering that the balance between the benefits and disadvantages is important for clinical adaptation, we provide a description of the efficacy and safety.

Three studies were undertaken on normal skin. [51] [52] [53] Two of the studies were RCTs. Two studies included adults, and one study included children. One study compared 1.5% OLG, 0.5% CHG, and placebo. 51 One study compared OLG with CHG; the concentration of OLG ranged from 0.02% to 0.2%, and that of CHG ranged from 0.05% to 0.5%. 53 One study determined the efficacy of OLG (concentration unknown) without a comparator 51 (Table 4 ).

In an RCT that assessed the efficacy of 1.5% OLG on normal skin, 52 OLG showed a significant reduction in bacterial counts after 10 min of application on both the abdomen and groin, compared to placebo. Furthermore, 1.5% OLG was not inferior to 0.5% CHG. Obatake et al. 51 collected samples from the skin (groin and umbilicus) both before and after disinfection with OLG (concentration unknown) and compared the presence or absence of bacteria. It was reported that OLG had a good bactericidal effect on both the groin and umbilical areas; however, specific data were unavailable. In a comparison of the number of viable bacteria before and after disinfection with various concentrations of OLG and CHG, 53 both after 30 s and 3 min of disinfectant application, the exponential reduction in total viable bacterial counts was higher in the OLG groups than in the CHG groups at all concentrations.

One study 54 evaluated wounded skin. The study population consisted of 50 adult inpatients who underwent clean or semiclean surgical procedures ( Table 4 ). The researchers applied 0.05% OLG to surgically sutured wounds on postoperative days 3, 7, and 14. No antiseptics were used for comparison. The efficacy rate determined by infection prevention and disinfection efficacy was 59.6% (95% confidence interval, 44.4-73.6). The efficacy was adjudged comprehensively based on progress after application and was not described in detail. 

Five studies evaluated the effect on SSI prevention. 26, [55] [56] [57] [58] Two studies were RCTs, and three were retrospective observational studies. One study included children, and the remaining four studies included adults. One study compared OLG, PVP-I, and CHG, 57 two studies compared OLG to PVP-I, 26, 56 and one study had no comparator. 58 One study (Table 5) . A retrospective study 58 examined the effect of OLG (concentration unknown) on the prevention of SSI in 100 patients undergoing gastrointestinal surgery, breast malignancy surgery, and inguinal hernia repair. This study reported only one case (1%) of SSI within 30 days postoperatively in the OLG group. However, 84% of all patients in the study had a low-risk National Nosocomial Infections Surveillance SSI risk index.

Obara et al. 26 undertook an RCT with a large sample size comparing 1.5% OLG with 10% PVP-I for disinfection during adult gastrointestinal surgery. A total of 587 patients were included; 294 and 293 patients in the 1.5% OLG and 10% PVI groups, respectively. The 30-day postoperative SSI rate was significantly lower in the 1.5% OLG group (7% in the 1.5% OLG group vs. 13% in the 10% PVP-I group; adjusted risk ratio, 0.48; 90% confidence interval, 0.03-0.74; p = 0.002). Similarly, in another retrospective study of adult gastrointestinal surgery patients, 57 the overall SSI incidence rate was significantly lower in the 1.5% OLG group (7.2% in the 1.5% OLG group vs. 10.0% in the 10% PVP-I group). This study 57 did not describe the detailed statistical methods and results. A retrospective study of clean 56 found no difference between the 1.5% OLG group and the 10% PVP-I group because no postoperative SSI occurred in either group. Regarding the comparison between 1.5% OLG and 1% CHG, a retrospective study of adult gastrointestinal surgery patients 57 revealed that the overall SSI incidence rate was significantly lower in the 1.5% OLG group (7.2% in the 1.5% OLG group vs. 9.8% in the 1% CHG group). However, this study 57 did not describe detailed statistical methods or results.

One RCT 55 compared single and double application of OLG (concentration unknown) for disinfection during laparoscopic or robotic standby gastrointestinal surgery in adults. The incident rate of all SSIs within 30 days after surgery was not significantly different between the two groups, and single application was noninferior to double application (3.1% in the single application group vs. 2.0% in the double application group, p = 0.537).

No relevant studies were identified.

The overall incidence of adverse events in OLG was very low, ranging from 2% to 5.8%. 26, 52, 56, 57, [59] [60] [61] Erythema, dermatitis, and pruritus each accounted for approximately 1.0%-1.9% of adverse events. 26, 52, 59, 61 The time of appearance of skin rash was approximately 3-17 days (median, 7 days) after application 60 (Table 6 ). The severity of the disease ranged from mild to moderate, with some cases of spontaneous resolution and resolution after oral antihistamine or topical corticosteroid use. 26, 52, 56, 57, [59] [60] [61] In an RCT 26 comparing 1.5% OLG and 10% PVP-I in adult gastrointestinal surgery, there was no significant difference in the rate of all adverse events between the two groups (2% in the 1.5% OLG group vs. 2% in the 10% PVP-I group, p = 1.00). Although the results of the detailed statistical analysis were not described, another RCT 52 also showed similar results (overall adverse event rate: 5.8% [3/ 52 cases] in the 1.5% OLG group vs. 7.4% [4/54 cases] in the 10% PVP-I group). In contrast, a retrospective study 60 comparing the incidence of postoperative dermatitis between OLG (concentration unknown) and PVP-I (concentration unknown) revealed that OLG yielded a significantly higher incidence (3.7% in the OLG group vs. 0.7% in the PVP-I group, p < 0.0001).

Only one study, a phase III trial, 52 compared OLG with CHG in terms of adverse event rates. The subjects were adults with healthy skin (abdomen and groin), and there was no difference in the rates of skin eruption between 1.5% OLG and 0.5% CHG (1.3% [3/237 cases] in the 1.5% OLG group vs. 0.8% [2/236 cases] in the 0.5% CHG group). However, the results of detailed statistical analysis were not described in this study. 52 Ongoing clinical studies Five ongoing clinical studies were identified. All are being undertaken in Japan, and three are related to SSI prevention. One study was related to disinfection at the time of blood culture collection, and one study was related to CRBSI (Table S3) .

I N THE PRESENT scoping review, we searched and summarized the evidence from existing studies on OLG. The retrieved published works were classified into 29 in vitro studies or animal studies and 18 clinical studies. In addition to common Gram-positive and Gram-negative bacteria, OLG showed bactericidal activity against MRSA and VRE. In clinical settings, although there is limited evidence on SSI prevention, 1.5% OLG might be more effective than 10% PVP-I and 1% CHG. However, its usefulness under other conditions is unclear.

In vitro studies have shown that the antimicrobial spectrum of OLG is broad and seems to be effective against resistant bacteria. However, its clinical usefulness remains unclear. Olanexidine gluconate showed a broad-spectrum bactericidal effect on both Gram-positive and Gramnegative bacteria 21 (Table 1) , and the bactericidal effects on resistant bacteria such as MRSA and VRE were characteristic 21 (Table 2 ). In emergency and intensive care, infections such as CRBSI and SSI caused by resistant bacteria (such as MRSA and VRE) are becoming a problem. [16] [17] [18] [19] In addition, existing antiseptics such as PVP-I and CHG are considered ineffective against these resistant bacteria. [16] [17] [18] [19] Therefore, OLG could be a useful disinfectant in emergency and intensive care settings. However, clinical studies on OLG are limited, and its clinical usefulness remains unclear.

In clinical settings, the usefulness of OLG is limited to its potential effect on SSI prevention. Moreover, the superiority of OLG over standard skin antiseptics such as chlorhexidine alcohol (CHG-AL) is unclear. All studies on the usefulness of OLG in clinical settings are related to SSI. An RCT 26 comparing 1.5% OLG with 10% PVP-I revealed that the overall SSI incidence rate was significantly lower in the OLG group. However, the comparator antiseptic used in this study was an aqueous formulation of PVP-I, which is a nonalcohol-based antiseptic and is already not 62 A study comparing 1.5% OLG with 1% CHG 57 also revealed that the overall SSI incidence rate was significantly lower in the OLG group. However, the interpretation of the results is limited by the fact that this was a retrospective study, and the results of detailed statistical analyses were not described. Therefore, the clinical usefulness of OLG against CHG-AL is still unclear.

In the future, more studies comparing OLG with standard skin disinfectants and more studies on OLG for infection prevention are needed. We reviewed studies on the in vitro pharmacological effects, antimicrobial spectrum, pharmacokinetics, and in vivo efficacy and safety on normal skin, wounded skin, and infection prevention. In the clinical setting, there were only studies related to the prevention of SSI with OLG, 26,56-58 and we did not identify any other studies on the prevention of infection, including CRBSI. Catheter- Retrospective study

Additional Supporting Information may be found in the online version of this article at the publisher's web-site: Table S1 . Search strategy on the applications of olanexidine. Table S2 . List of excluded studies. Table S3 . Ongoing studies on olanexidine. 

Impact of surgical site infection after colorectal surgery on hospital stay and medical expenditure in Japan

Matsumoto T. The additional costs of catheter-related bloodstream infections in intensive care units

Clinical and economic outcomes in critically ill patients with nosocomial catheterrelated bloodstream infections

The attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: A prospective, matched analysis

Centers for disease control and prevention guideline for the prevention of surgical site infection

New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective

Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters

Guidelines for the prevention of intravascular catheter-related infections

Prospective randomized trial of 10% povidone-iodine versus 0.5% tincture of chlorhexidine as cutaneous antisepsis for prevention of central venous catheter infection

Effect of skin antiseptic solutions on the incidence of catheter-related bloodstream infection: a systematic review and network metaanalysis

epic3: national evidence-based guidelines for preventing healthcareassociated infections in NHS hospitals in England

Biocide susceptibility of the Burkholderia cepacia complex

APSIC guidelines for disinfection and sterilization of instruments in health care facilities

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

Annual report of JHAIS SSI surveillance

Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate

Evaluation of bactericidal activity and lag of regrowth (postantibiotic effect) of five antiseptics on nine bacterial pathogens

Bactericidal effects of antiseptics and disinfectants against methicillin-resistant Staphylococcus aureus

Efficacy of hand disinfectants against vancomycin-resistant enterococci in vitro

Fast-acting bactericidal activity of olanexidine gluconate against qacA/B-positive methicillin-resistant Staphylococcus aureus

Evaluation of in vitro bactericidal activity of 1.5% olanexidine gluconate, a novel biguanide antiseptic agent

Evaluation of fast-acting bactericidal activity and substantivity of an antiseptic agent, olanexidine gluconate, using an ex vivo skin model

Bactericidal effects and mechanism of action of olanexidine gluconate, a new antiseptic

The minimum killing concentrations of chlorhexidine gluconate and olanexidine gluconate on clinically isolated S.aureus strains

Novel antiseptic compound OPB-2045G shows potent bactericidal activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus both in vitro and in vivo: a pilot study in animals

Aqueous olanexidine versus aqueous povidone-iodine for surgical skin antisepsis on the incidence of surgical site infections after clean-contaminated surgery: a multicentre, prospective, blinded-endpoint, randomised controlled trial

PRSIMA extension for scoping reviews (PRISMA-ScR): checlist and explanation

Otsuka Pharmaceutical Factory I Sterilizing Disinfectant for External Skin Olanexidine Disinfectant Solution 1.5% (Olanexidine Gluconate Solution)

Electron-microscopic Study of the Bactericidal Effect of OPB-2045, a New Disinfectant Produced from Biguanide Group Compounds, Against Methicillin-resistant Staphylococcus aureus

Electronmicroscopic study of the bactericidal effect of OPB-2045, a new mono-biguanide disinfectant produced from biguanide group compounds, against Pseudomonas aeruginosa

Anti-inflammatory effects of olanexidine gluconate on oral epithelial cells

To be kept in mind! Disinfectant basics and pitfalls (3). Low-level disinfectants

Virucidal efficacy of olanexidine gluconate as a hand antiseptic against human norovirus

Olanexidine gluconate formulations as environmental disinfectants for enveloped viruses infection control

Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis

Effects of olanexidine gluconate on preoperative skin preparation: An experimental study in cynomolgus monkeys

Guideline for Disinfection and Sterilization in Healthcare Facilities

Metabolism of a new bactericidal antiseptic, OPB-2045, in rats following subcutaneous administration

Percutaneous Absorption and Tissue Distribution of 1-(3,4-dichlorobenayl)-5-octylbiguanide (OPB-2045) in Rats. Xenobiotic Metab. Dispos

In vitro characterization of the oxidative cleavage of the octyl side chain of olanexidine, a novel antimicrobial agent, in dog liver microsomes

Oxidative cleavage of the octyl side chain of 1-(3,4-dichlorobenzyl)-5-octylbiguanide (OPB-2045) in rat and dog liver preparations

Distribution (Autoradiography) of a new synthetic antibacterial agent OPB-2045 in rats

Ó 2022 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine

Pharmacokinetics of OPB-2045 in Rats: systemic exposure following oral, subcutaneous, and intravenous administration

Absorption and excretion of OPB 2045 following a single oral administration to rats

Absorption, distribution and excretion of OPB 2045 following a single subcutaneous administration to beagle dogs

Absorption, distribution and excretion of OPB-2045 following a single subctaneous administration to rats

Reproductive and developmental toxicity studies of OPB-2045(4)À pre-and postnatal development study in rats by subcutaneous administration

Reproductive and developmental toxicity studies of OPB-2045(3)

Reproductive and developmental toxicity studies of OPB-2045(2)

Reproductive and developmental toxicity studies of OPB-2045(1) -fertility study in rats by subcutaneous administration

Efficacy of surgical field disinfection

A phase III clinical study of novel antiseptic, OPB-2045G solution (Olanedine Antiseptic solution 1.5%)

Antiseptic effect of OPB-2045 solution applied to normal skin. Environ

Efficacy and safety of OPB-2045, a new antiseptic, in post-operative wounds

Disinfection with single or double usage of new antiseptic olanexidine gluconate in general surgery: a randomized study

Efficacy of the new antiseptic solution "Olanedineâ antiseptic applicator" in pediatric surgery

Experience with olanexidine, a surgical site skin disinfectant

Does the new disinfectant (olanexidine gluconate) reduce SSI?

A case of allergic contact dermatitis caused by Olanedine solution-A diagnostic patch-testing method involving dried filter paper

Dermatitis caused by olanedine (olanexidine gluconate) and povidone iodine

Allergic contact dermatitis caused by Olanedineâ (olanexidine gluconate), a new antiseptic

Centers for disease control and prevention guideline for the prevention of surgical site infection

Matsumoto T. The additional costs of catheter-related bloodstream infections in intensive care units

Japan: The effectiveness of Antiseptic solution for Prevention of intravenous catheter-related blood stream infection with OLanexidine glucOnate

Clinical phase I study of OPB-2045, a new antiseptic I. Skin safety assessment

Clinical Phase I Study of OPB-2045, A New Antiseptic II. Investigation of the safety and pharmacokinetic profile of OPB-2045 by single application

Clinical phase I study of OPB-2045, a new antiseptic III. Investigation of the safety and pharmacokinetic profile of OPB-2045 by repeated applications

Clinical phase I study of OPB-2045, a new antiseptic IV. Safety on scarified skin, contact sensitivity, contact photosensitivity, and potential to induce urticarial reactions

Significance and classification of disinfection, Q&A on disinfectants commonly used for biological organisms 11

Profile of new drug

 64 This review does have some limitations. The studies reviewed were all undertaken in Japan and, due to the novelty of the drug, the number of studies was limited.

O LANEXIDINE GLUCONATE IS a novel disinfectant with a broad spectrum and bactericidal effect against organisms, including MRSA and VRE, that are resistant to existing disinfectants such as PVP-I and CHG. Olanexidine gluconate might be more effective than PVI and CHG for SSI prevention. However, the clinical usefulness of OLG is unclear due to the limited number of clinical studies. In addition, clinical research is limited to studies targeting SSI prevention, and there is no clinical study on CRBSI. Therefore, further clinical studies are needed not only on the prevention of SSI but also on the prevention of CRBSI.